Table of properties of different domains that bind to
phospho-peptides.
(The binding is at phospho-serine / phospho-threonine
/ phospho-tyrosine denoted by X)
(Look out for the above
color code)
No |
Binding
Domain |
DomainStr. Eg. |
Examples:
Structure - Protein - Binding site - View |
Consensus binding site* – Prosite Entry |
Annotation - References |
||
1 |
1G3G, 1J4O, 1K3J, 1QU5. |
No name. |
SLEVXEADATFAK. |
EDIXYLD. |
In eukaryotes, many FHA domain-containing
proteins localize to the nucleus, where they participate in establishing or
maintaining cell cycle checkpoints, DNA repair, or transcriptional
regulation. [1],
[2],
[3],
[4]. |
||
DNA repair protein. |
EDIXYLD. |
||||||
Synthetic. |
RHFDXYLIRR. |
||||||
DNA repair protein. |
EDIXYLD. |
||||||
DNA
repair protein. |
EVELXQELP. |
||||||
DNA
repair protein. |
KKMTFQXPTDPLE. |
||||||
DNA
repair protein. |
SLEVXEADATFVQ. |
||||||
DNA repair protein. |
EDIXYLD. |
||||||
DNA
repair protein. |
EVELXQELP. |
||||||
DNA
repair protein. |
KKMTFQXPTDPLE. |
||||||
DNA
repair protein. |
SLEVXEADATFVQ. |
||||||
2 |
Ps-Raf259 Peptide. |
KSQRQRSTXTPNVHM. |
QSYXV. |
14-3-3 homologues
mediate signal transduction by binding to phosphoserine containing proteins.
[5],
[6]. |
|||
Phosphopeptide. |
RLYHXLPA. |
||||||
Phosphopeptide. |
ARSHXYPA/RSHXYPA |
||||||
Plasma
Membrane H+ Atpase. |
QSYXV. |
||||||
Plasma
Membrane H+ Atpase. |
QSYXV. |
||||||
3 |
1J6Y. |
Y(Sep)Pt(Sep)S
Peptide. |
YXPTXPS. |
YXPTXPS. |
Domain with 2
conserved Trp (W) residues; Also known as the WWP or rsp5 domain. Binds
proline-rich polypeptides. [7],
[8],
[9]. |
||
M-Phase
Inducer Phosphatase 3. |
EQPLXPVTDL. |
||||||
Microtubule-Associated
Protein Tau. |
KVSVVRXPPKSPS. |
||||||
4 |
Ci Man-6-P Receptor. |
FHDDXDEDLLHI. |
FHDDXDEDLLHI. |
||||
5 |
Phosphocarrier Protein Hpr. |
~TVNLKXIMGVM~ |
~TVNLKXIMGVM~ |
Serine kinase of the
HPr protein regulates carbohydrate metabolism [Signal transduction
mechanisms]. [12],
[13]. |
|||
6 |
1VHR. |
DDE(Ahp)(Tpo)G (Ptr)VATR. |
DDEXXGXVATR. |
DDEXXGXVATR. |
Dual specificity
phosphatases (DSP); Ser/Thr and Tyr protein phosphatases. Characterized as
VHR- or Cdc25-like. [14]. |
||
7 |
1JJS. |
Creb. |
~SRRPXYRKIL~ |
~SRRPXYRKIL~ |
CBP and P300 bind to
the CREB via a domain known as KIX. The KIX domain of CBP also binds to
transactivation domains of other nuclear factors including Myb and Jun. [15]. |
||
8 |
1DD1. |
Smad2
Protein. |
~VRCSXMX. |
~VRCSXMX. |
MH2 domain. This is
the MH2 (MAD homology 2) domain found at the carboxy terminus of MAD related
proteins. The MH2 domain mediates interaction with a wide variety of
proteins. [16],
[17]. |
||
9 |
1ERJ. |
GLL(Tpo)PPQSG. |
GLLXPPQSG. |
GLLXPPQSG. |
WD40 domain, found in
a number of eukaryotic proteins that cover a wide variety of functions
including adaptor/regulatory modules in signal transduction, pre-mRNA processing
and cytoskeleton assembly. [18]. |
||
10 |
|
Capk.
– SEP & TPO. |
~AAKKGXEQESV~ ~EEIRVXINEKC~
~KGRTWXLCGTP~ |
~EEIRVXINEKC~
~AAKKGXEQESV~ ~KGRTWXLCGTP~ |
cAMP-dependent protein
kinase inhibitor (PKI). Members of this family are extremely potent
competitive inhibitors of camp-dependent protein kinase (Capk) activity.
These proteins interact with the catalytic subunit of the enzyme after the
cAMP-induced dissociation of its regulatory chains. [23],
[19],
[20],
[21],
[22],
[24]. |
||
Capk.
– SEP & TPO. |
~EEIRVXINEKC~ ~KGRTWXLCGTP~ |
||||||
Capk.
– SEP & TPO. |
~EEIRVXINEKC~ ~KGRTWXLCGTP~ |
||||||
Capk.
– SEP & TPO. |
~EEIRVXINEKC~ ~KGRTWXLCGTP~ |
||||||
Capk.
– SEP & TPO. |
~EEIRVXINEKC~ ~KGRTWXLCGTP~ |
||||||
Capk.
– SEP & TPO. |
~AAKKGXEQESV~ ~EEIRVXINEKC~
~KGRTWXLCGTP~ |
||||||
Capk.
– SEP & TPO. (Domain
is also phosphorylated) |
~EEIRVXINEKC~ ~KGRTWXLCGTP~ (~RTGRRAXIHD.) |
||||||
Capk.
– SEP & TPO. |
~AAKKGXEQESV~ ~RIGRFXEPHAR~ ~EEIRVXINEKC~ ~KGRTWXLCGTP~ |
||||||
11 |
1F32. |
Pepsin A. |
~TFEATXQELSI~ |
~TFEATXQELSI~ |
Ascaris pepsin
inhibitor-3 (API3); protein inhibitor that reversibly inhibits aspartic
proteinase cathepsin E, and gastric enzymes pepsin and gastricsin. [25]. |
||
12 |
Epithelial-Cadherin. |
~VFDYEGXGXEAASL-XSLNSS~ |
~VFDYEGXGXEAASLXSL-NSS~ |
ARM has been
implicated in mediating protein-protein interactions, but no common features
among the target proteins recognized by the ARM repeats have been identified.
[26],
[27],
[28],
[29]. |
|||
13 |
1VIN. |
Cdk2. |
~PVRTYXHEVVT~ |
~PVRTYXHEVVT~ |
Protein binding domain
functioning in cell-cycle and transcription control. Present in cyclins,
TFIIB and Retinoblastoma (RB). The cyclins consist of 8 classes of cell cycle
regulators that regulate cyclin dependent kinases (CDKs). [38],
[30],
[31],
[32],
[33],
[34],
[35]. |
||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. P33 protein kinase. |
~PVRTYXHEVVT~ |
||||||
Cdk2. |
~PVRTYXHEVVT~ |
||||||
14 |
|
Cell Division Protein Kinase 2. |
~PVRTYXHEVVT~ |
~PVRTYXHEVVT~ |
Cyclin-dependent
kinase inhibitor. Cell cycle progression is negatively controlled by
cyclin-dependent kinases inhibitors (CDIs). CDIs are involved in cell cycle
arrest at the G1 phase. [36]. |
||
15 |
1H8F, 1I09. |
Serine/Threonine Protein Kinase |
~GATMKXFCGTP~ |
~GATMKXFCGTP~ |
Glycogen synthase
[Carbohydrate transport and metabolism]. [37]. |
||
Serine/Threonine Protein Kinase |
~GATMKXFCGTP~ |
||||||
16 |
|
|
|
??? |
SH2 domains typically
bind pTyr-containing ligands via two surface pockets, a pTyr and hydrophobic
binding pocket, allowing proteins with SH2 domains to localize to tyrosine
phosphorylated sites. |
||
17 |
|
|
|
??? |
|
|
|
18 |
|
|
??? |
|
[1]. |
||
19 |
|
|
??? |
|
[1]. |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
??? – Interesting domains for which structures are
not readily available.
* - Consensus from binding sites listed in column
4 and from data in Prosite (if available).